Abscopal 5001 Clinical Trial
A Phase 2 Trial of Cryosurgical Freezing and Multiplex Immunochemotherapy in Patients with Metastatic Solid Cancer
| Indication: | Metastatic Androgen-Independent Prostate Cancer |
| Endpoints: | (1) Proportion of patients achieving ≥ 50% decline in PSA at week 12 from baseline; (2) Radiologic cancer shrinkage according to iRECIST criteria |
| No. Investig. Sites: | 2 approved and functioning; 2 pending |
| No. Subjects: | 32 |
| IND Exemp. (FDA): | Granted, Dec 2018 |
| IRB: | Advarra, Columbia, MD (Approved, Feb 2019) |
| Contract Res.Org. | TD2, Phoenix, AZ |
Abscopal 1001 Clinical Trial
Phase 2 Trial of Cryosurgical Freezing and Intratumoral Combination Immunotherapy in Men with Metastatic Prostatic Adenocarcinoma.
| Indication: | Metastatic Androgen-Independent Prostate Cancer |
| Endpoints: | (1) Proportion of patients achieving ≥ 50% decline in PSA at week 12 from baseline; (2) Radiologic cancer shrinkage according to iRECIST criteria |
| No. Investig. Sites: | 2 approved and functioning; 2 pending |
| No. Subjects: | 32 |
| IND Exemp. (FDA): | Granted, Dec 2018 |
| IRB: | Advarra, Columbia, MD (Approved, Feb 2019) |
| Contract Res.Org. | TD2, Phoenix, AZ |
Rampart Health 